{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Ma W"],"pubmed_abstract":["<h4>Objective</h4>Radical surgical resection is the only potentially curative treatment for perihilar cholangiocarcinoma (PHC) patients. However, data on left-sided hemihepatectomy (LH) and right-sided hemihepatectomy (RH) outcomes for Bismuth-Corlette type IV PHC are scarce and controversial. This study aimed to explore surgical and long-term outcomes of LH and RH in these patients.<h4>Methods</h4>Medical records of Bismuth type IV PHC patients who had liver resection from 2009 to 2018 were retrospectively analyzed. Surgical results and long-term survival were the primary outcomes, compared via one-to-one propensity score matching (PSM).<h4>Results</h4>218 Bismuth type IV PHC patients (146 LH, 72 RH) were analyzed. The RH group had a higher proportion of preoperative biliary drainage (p = 0.02) and more frequent portal vein embolization (p < 0.0001). R0 resection rate was 90.37% (197/218) with no significant LH-RH difference. Post-operative severe complication (grades 3-5) and 90-day mortality rates were comparable. Overall survival was similar (overall cohort: p=0.21; matched cohort: p=0.54). But in the overall cohort, R0-resected RH patients had marginally better survival (p = 0.064). Prognostic factors included carbohydrate antigen 19-9 (CA19-9), age, tumor vascular invasion, and severe post-operative complications.<h4>Conclusions</h4>The postoperative morbidity and mortality rate was comparable between LH and RH for Bismuth type IV PHC. Although RH showed a favorable survival from the Kaplan-Meier survival curve, no significant difference was observed in overall survival after LH versus RH for the overall cohort and the matched cohort after PSM."],"journal":["Frontiers in oncology"],"pagination":["1663334"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12689366"],"repository":["biostudies-literature"],"pubmed_title":["Right-side versus left-side hemihepatectomy for the treatment of Bismuth type IV perihilar cholangiocarcinoma: a comparative study."],"pmcid":["PMC12689366"],"pubmed_authors":["Huang Y","Yan P","Xie Z","Ao J","Jiang X","Hu M","Wang J","Ma W"],"additional_accession":[]},"is_claimable":false,"name":"Right-side versus left-side hemihepatectomy for the treatment of Bismuth type IV perihilar cholangiocarcinoma: a comparative study.","description":"<h4>Objective</h4>Radical surgical resection is the only potentially curative treatment for perihilar cholangiocarcinoma (PHC) patients. However, data on left-sided hemihepatectomy (LH) and right-sided hemihepatectomy (RH) outcomes for Bismuth-Corlette type IV PHC are scarce and controversial. This study aimed to explore surgical and long-term outcomes of LH and RH in these patients.<h4>Methods</h4>Medical records of Bismuth type IV PHC patients who had liver resection from 2009 to 2018 were retrospectively analyzed. Surgical results and long-term survival were the primary outcomes, compared via one-to-one propensity score matching (PSM).<h4>Results</h4>218 Bismuth type IV PHC patients (146 LH, 72 RH) were analyzed. The RH group had a higher proportion of preoperative biliary drainage (p = 0.02) and more frequent portal vein embolization (p < 0.0001). R0 resection rate was 90.37% (197/218) with no significant LH-RH difference. Post-operative severe complication (grades 3-5) and 90-day mortality rates were comparable. Overall survival was similar (overall cohort: p=0.21; matched cohort: p=0.54). But in the overall cohort, R0-resected RH patients had marginally better survival (p = 0.064). Prognostic factors included carbohydrate antigen 19-9 (CA19-9), age, tumor vascular invasion, and severe post-operative complications.<h4>Conclusions</h4>The postoperative morbidity and mortality rate was comparable between LH and RH for Bismuth type IV PHC. Although RH showed a favorable survival from the Kaplan-Meier survival curve, no significant difference was observed in overall survival after LH versus RH for the overall cohort and the matched cohort after PSM.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-06T01:21:04.459Z","creation":"2026-05-24T03:11:37.964Z"},"accession":"S-EPMC12689366","cross_references":{"pubmed":["41383519"],"doi":["10.3389/fonc.2025.1663334"]}}